Proactive update13 Feb 2023 10:28
Proactive update
"The success of a human trial demonstrating that an AvidiMab-modified DNA vaccine, delivered via a needle-free injection, can induce both T-cell and antibody responses, with no safety concerns, is a pivotal proof point for Scancell's clinical strategy,” said CEO Durrant.
The company will now seek a partner to progress the COVIDITY vaccine programme and focus its resources on its portfolio of innovative immuno-oncology drug candidates.
Sounds all very upbeat. Long may it continue good update from Proactive